Takara Bio Group strives to proactively disclose information to its stakeholders by accurately assessing the risks and opportunities related to climate change, clarifying the impact on its business operations, and clarifying measures to be taken as we work towards the realization of a sustainable society and the sustainable growth of our Group. All assessments are based on scenario analysis in accordance with the Task Force on Climate-related Financial Disclosures (TCFD).
1. Governance
As a global company with operations around the world, Takara Bio Group regards climate change as an important management issue. Under the supervision of the Board of Directors, Takara Bio Group Sustainability Promotion Committee, the decision-making body for environmental issues, examines scenarios related to climate change, identifies risks and opportunities, and discusses countermeasures, which are reflected in the business operations of each group company. This Committee reports to the Board of Directors at least once a year and discloses information to stakeholders based on TCFD (Figure 1).
2. Strategy
Takara Bio Group recognizes that the global average temperature increase due to climate change will have an enormous impact on society, and believes that it is important to contribute to activities to curb temperature increases. Our Group is identifying the business impacts of climate-related risks and opportunities, and is formulating strategies to enhance its ability to respond to a 2℃ or lower scenario. Scenario analysis was carried out using a “2℃ or lower scenario,” in which the average global temperature increase is restricted to 2℃ or lower than pre-industrial levels, and a “4℃ scenario,” in which the average global temperature is increased by 4℃. This analysis evaluated the degree of impact on our business operations and the likelihood of these scenarios occurring, examined countermeasures, and summarized the risks and opportunities that would have a large impact on our Group in Table 1. In the scenario analysis, we referred to the Intergovernmental Panel on Climate Change (IPCC), RCP2.6 (2℃ or lower scenario), RCP8.5 (4℃ scenario), and WRI Aqueduct (global water risk mapping tool developed by the World Resources Institute).
2℃ or lower scenario
Social changes |
Risks/ Opportunities |
Type |
Business Impact |
Time Axis† |
Financial |
Business Risks/ |
Countermeasure |
Rising energy costs |
Migration risk |
Market |
Risk of financial impact from higher energy prices resulting in increased manufacturing costs |
Medium term |
Medium |
Medium |
|
|
|||||||
Orders and regulations on products and services |
Migration risk |
Policy and law |
Risk that use of specified substances will become prohibited by laws and regulations causing a suspension in the supply of raw materials such as plastic products, making the supply of products and services difficult |
Medium - long term |
Medium |
Medium |
|
|
4℃ scenario
Social changes |
Risks/ Opportunities |
Type |
Business Impact |
Time Axis† |
Financial |
Business Risks/ Opportunities§ |
Resilience by Takara Bio |
Frequent and serious abnormal weather (heavy rains, floods, etc.) |
Physical risk |
Acute |
Risk of financial impact due to suspension in the supply of products and services due to damage to manufacturing sites caused by flood, etc. |
Medium - long term |
Large |
Medium |
|
Risk of damage to manufacturing sites due to flood damage, etc. and the need for equipment replacement, resulting in financial impact. Or risk that business continuity becomes difficult due to leakage of hazardous substances, etc. due to damage to biohazard facilities |
Medium - long term |
Medium |
Medium |
||||
Risk of financial impact due to disruption of supply chain due to flood, etc. and suspension of supply of products and services |
Medium - long term |
Large |
Medium |
||||
Risk of financial impact due to suspension of operations at manufacturing sites and supply of products and services due to drought |
Medium term |
Large |
Medium |
||||
Infectious disease outbreak |
Physical risk |
Chronic |
Risk of reduced economic and R&D activities due to infectious disease outbreaks. Or the risk that the supply chain will be disrupted, resulting in a shortage of raw materials, etc., resulting in financial impact from the suspension of the supply of products and services. |
Medium term |
Large |
Medium |
|
Development of new products and services through R&D and technological innovation |
Opportunities |
Products/ Services |
Opportunities for increased research and development in this field and expansion of related new products and services due to the spread of climate-related infectious diseases |
Medium term |
ー |
Medium |
|
† Time axis
Medium-Term: up to 2030 Long-term: after 2030
‡ Impact
The impact of consolidated operating income or consolidated net assets is evaluated based on the following criteria: small (less than 1 billion yen), medium (1 billion to 3 billion yen), and large (3 billion yen or more)
§ Business Risks and Opportunities
Comprehensive evaluation considering financial impact and potential occurrence
3. Risk Management
Takara Bio Group has established the framework to minimize adverse effects and losses caused by the materialization of risks, including scenario analysis and the assessment of risks associated with climate change in line with TCFD recommendations. We are assessing the degree of impact and the risk level depending on the frequency of occurrence at major manufacturing sites where business continuity and financial impact are significant. Identified risks, opportunities and countermeasures are discussed by the Sustainability Promotion Committee, which is chaired by the President and is comprised of executive officers responsible for each of our business segments, and reports to the Board of Directors.
4. Indicators and Targets
In its Sustainability Management Promotion Policy formulated in June 2021 (Updated June 2023), Takara Bio Group focused on the environment as one of its key initiatives, and set a target of reducing CO2 emissions per unit of sales in fiscal 2026 to 50% of fiscal 2019 levels. As of fiscal 2024, our Group's CO2 emissions (basic unit) were 89% of the fiscal 2019 level (Table 2).
We will continue to review risks and opportunities and implement specific measures and reflect them in our medium- to long-term management strategy to enhance our management strategy against climate change.
(FY) |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Comparison with emissions in the base year (FY2019) (%) |
100 |
86 |
76 |
57 |
55 |
89 |
Basic unit (CO2 emission per unit of sales) |
37 |
32 |
28 |
21 |
20 |
33 |
CO2 emission (t-CO2) |
13,188 |
10,892 |
12,836 |
14,253 |
15,692 |
14,211 |
Takara Bio |
5,894 |
6,822 |
8,590 |
9,833 |
10,418 |
11,107 |
Takara Biotechnology (Dalian) |
3,869 |
4,039 |
4,060 |
4,126 |
4,619 |
2,555 |
Other business location |
3,425 |
31 |
186 |
294 |
655 |
549 |